No Data
No Data
Percheron Therapeutics Names Chief Medical Advisor
Percheron Therapeutics (ASX:PER) appointed Cathryn Clary as chief medical advisor, effective immediately, according to a Monday filing with the Australian bourse. Clary most recently served as consult
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%
Percheron Therapeutics (ASX:PER) completed the enrollment of 48 non-ambulant boys for its phase 2b trial investigating the use of the ATL1102 medication to treat Duchenne muscular dystrophy, according
Here's Why We're Watching Percheron Therapeutics' (ASX:PER) Cash Burn Situation
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate
Percheron Therapeutics (ASX:PER) secured an intellectual property protection grant from the US Patent and Trademark Office for its lead medicinal candidate ATL1102 to treat Duchenne Muscular Dystrophy
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102
Percheron Therapeutics (ASX:PER) said that the World Health Organization chose avicursen as the proposed international nonproprietary name for its investigational drug candidate, ATL1102, according to
Shareholders Have Faith in Loss-making Percheron Therapeutics (ASX:PER) as Stock Climbs 26% in Past Week, Taking Five-year Gain to 142%
No Data